Paul Tudor Jones's IMCR Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 22,231 shares of Immunocore Holdings plc (IMCR) worth $771,638, representing 0.00% of the portfolio. First purchased in 2025-Q1, this short-term holding has been held for 4 quarters.
Based on 13F filings, Paul Tudor Jones has maintained this position in IMCR for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 1,092 shares. Largest reduction occurred in Q2 2025, reducing 33,354 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Immunocore Holdings plc (IMCR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Immunocore Holdings plc (IMCR) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +1,092 | Add 5.17% | 22,231 | $34.71 |
| Q2 2025 | -33,354 | Reduce 61.21% | 21,139 | $31.38 |
| Q1 2025 | +54,493 | New Buy | 54,493 | $29.67 |
Paul Tudor Jones's Immunocore Holdings plc Investment FAQs
Paul Tudor Jones first purchased Immunocore Holdings plc (IMCR) in Q1 2025, acquiring 54,493 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Immunocore Holdings plc (IMCR) for 4 quarters since Q1 2025.
Paul Tudor Jones's largest addition to Immunocore Holdings plc (IMCR) was in Q1 2025, adding 54,493 shares worth $1.62 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 22,231 shares of Immunocore Holdings plc (IMCR), valued at approximately $771,638.
As of the Q4 2025 filing, Immunocore Holdings plc (IMCR) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Immunocore Holdings plc (IMCR) was 54,493 shares, as reported at the end of Q1 2025.